MedTrace Logo

Post Marketing Observational Study on Paricalcitol IV Administered to Venezuelan Patients

NCT01758289 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 105

Last updated 2014-11-17

Study results available
· View outcomes & findings →

Summary

This study was designed to evaluate the effectiveness, safety, and impact on quality of life when paricalcitol (Zemplar® intravenous \[IV\]) is administered in Venezuelan patients on hemodialysis who are at risk of developing secondary hyperparathyroidism associated with stage V chronic kidney disease.

Conditions

  • Chronic Kidney Disease Stage V
  • Hemodialysis

Sponsors & Collaborators

  • AbbVie (prior sponsor, Abbott)

    lead INDUSTRY

Principal Investigators

  • Jeanine Obage, MD · Abbott

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2013-11-30
Completion
2013-11-30

Countries

  • Venezuela

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01758289 on ClinicalTrials.gov